Currently Viewing:
Newsroom

What We're Reading: Impact of Authorized Generics; Harms of Fundraising for Healthcare; White House Mulls ACA Alternative

AJMC Staff
Authorized generics, released by brand-pharmaceutical companies as a way to deal with competition, can be as profitable as, if not more profitable than, brand-name drugs; an increasing reliance on fundraising appeals for healthcare needs can widen existing disparities and distort markets, particularly for prescription drugs; the Trump administration is considering releasing a healthcare plan in the fall.

Authorized Generics Hindering Competition

Authorized generics, released by brand-pharmaceutical companies as a way to deal with competition, can be as profitable as, if not more profitable than, brand-name drugs, Kaiser Health News reported. They do not promote competition, the chief medical officer for drug-benefit manager OptumRx told Congress in April; others say the products may raise prices in the short term. There are now nearly 1200 authorized generics approved in the United States.



Fundraising Appeals for Healthcare Can Worsen Disparities, Distort Markets

An increasing reliance on fundraising appeals for healthcare needs can widen existing disparities and distort markets, particularly for prescription drugs, The Los Angeles Times reported. Turning to charity also means patients and their families must devote precious time and energy to raising money. Those turning to fundraising typically have insurance, but struggle with high deductibles or the loss of income due to illness. An executive vice president with the National Multiple Sclerosis Society said the underinsured are affected the most.



White House Considers Releasing Ideas to Replace Affordable Care Act

The Trump administration is considering releasing a healthcare plan in the fall, The Wall Street Journal reported; the White House reportedly wants to be prepared if the Affordable Care Act is overturned. Some options under discussion are protections for people with preexisting conditions, selling insurance across state lines, expanding health savings accounts, linking price transparency to quality metrics, and other moves. But the timing of the announcement is uncertain, and the ideas have yet to win the president’s approval; some are skeptical that a plan will be announced.

Related Articles

What We're Reading: Switching to Generics; Cutting Opioid Production; Updating Alzheimer's Tests
Humana Sues 37 Drug Makers, Alleges Conspiracy to Fix Prices of Certain Generics
Substituting Brand-Name Combinations for Generics Could Have Saved Medicare $925 Million in 2016
What We're Reading: Gene-Editing Babies; Maine Work Requirements; Trade Deal to Delay Generics
Medicare Beneficiaries May Pay More for Some Generics Than Brand-Name Drugs
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up